IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$8.88 USD
+0.05 (0.57%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $8.90 +0.02 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
IGM Biosciences, Inc. (IGMS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.40 | $48.00 | $11.00 | 140.99% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for IGM Biosciences, Inc. comes to $21.40. The forecasts range from a low of $11.00 to a high of $48.00. The average price target represents an increase of 140.99% from the last closing price of $8.88.
Analyst Price Targets (10)
Broker Rating
IGM Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.90 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.90 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 10% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.90 | 1.90 | 1.90 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/13/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/12/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
3/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/8/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
3/8/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.90 |
ABR (Last week) | 1.90 |
# of Recs in ABR | 10 |
Average Target Price | $21.40 |
LT Growth Rate | 14.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 72 of 253 |
Current Quarter EPS Est: | 0.03 |